相关实验视频
Updated: Jun 7, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
306
急性肺栓塞的管理:一篇评论
Abhay Bhave1, Harjit Dumra2, Sandeep Bansal3
1Consultant Hematologist, Department of Haematology, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India, Corresponding Author.
The Journal of the Association of Physicians of India
|November 20, 2024
概括
在印度,肺栓塞 (PE) 的诊断和治疗需要使用临床标准和生物标志物进行风险分层. 最佳管理包括抗凝剂和潜在的血栓抑制剂,并考虑长期治疗以预防复发.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 内部医学 内部医学
背景情况:
- 肺栓塞 (PE) 是致病和死亡的重要原因,特别是在住院患者中.
- 在印度,PE经常被诊断不足和管理不善,导致不良结果.
- 以前的印度共识指南已经存在,但新的数据需要进行更新的审查.
研究的目的:
- 审查和整合最近关于急性PE最佳诊断,风险评估和治疗的发现.
- 为根据风险分层选择适当的诊断调查提供指导.
- 更新针对急性PE抗凝剂和血栓抑制剂治疗的建议.
主要方法:
- 审查最近的研究,包括印度的数据,关于PE诊断和管理.
- 强调使用临床预测标准 (PESI,Hestia) 和生物标志物 (RV功能障碍,心肌损伤) 的风险分层.
- 讨论各种诊断方式 (D-二次体,心电图,成像) 和治疗选择 (抗凝剂,血栓抑制剂).
主要成果:
- 急性PE患者需要风险分层来指导管理决策.
- 临床预测标准和生物标志物对于评估早期死亡风险至关重要.
- 应根据个体患者的风险概况选择一系列的诊断测试.
- 抗凝剂是治疗的支柱,新型口服抗凝剂提供了优势.
- 对于特定的急性PE病例,强烈支持进行血栓缓解疗法.
结论:
- 风险分层对于有效管理急性PE患者至关重要.
- 适当选择诊断工具和治疗方法可以改善结果.
- 抗凝药,包括新的药物,以及合理使用血栓抑制剂是治疗的关键组成部分.
- 长期抗凝药可能是必要的,以防止在选定的个体中复发PE.
相关概念视频
01:29Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
150
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
150
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:30Pneumonia V: Nursing management and Prevention
1.9K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
1.9K
01:26Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160
01:27Pneumothorax-II
120
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
120